



REMARKS


Applicants submit these remarks to accompany this Preliminary Amendment. No new matter is added.

The specification is amended at page 7, line 25 to indicate SEQ ID NO:7 instead of SEQ ID NO:9, to be consistent with page 65, line 22, which correctly identifies the two reverse control oligonucleotides as SEQ ID NO:6 and 7. Page 52, line 28 is amended to complete the phrase "in the art," the meaning of which is evident for the context.

All of the claims in the application are now in condition for examination. Favorable consideration and a Notice of Allowance are earnestly solicited.

If questions remain regarding this application, the Examiner is invited to contact the undersigned at (206) 628-7650.

Respectfully submitted,
Birgit K. Jaitner et al.
DAVIS WRIGHT TREMAINE LLP

By 
Jane E. R. Potter
Registration No. 33,332

2600 Century Square
1501 Fourth Avenue
Seattle, WA 98101-1688
Phone: (206) 628-7650
Facsimile: (206) 628-7699